114 related articles for article (PubMed ID: 2670209)
1. A phase-II study of adoptive immunotherapy with continuous infusion of interleukin-2 in children with advanced neuroblastoma. A report on 11 cases.
Favrot M; Floret D; Michon J; Negrier S; Bouffet E; Coze C; Gaspard M; Cochat P; Thiesse P; Andreu G
Cancer Treat Rev; 1989 Jun; 16 Suppl A():129-42. PubMed ID: 2670209
[TBL] [Abstract][Full Text] [Related]
2. Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation.
Favrot MC; Floret D; Negrier S; Cochat P; Bouffet E; Zhou DC; Franks CR; Bijman T; Brunat-Mentigny M; Philip I
Bone Marrow Transplant; 1989 Sep; 4(5):499-503. PubMed ID: 2790327
[TBL] [Abstract][Full Text] [Related]
3. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
[TBL] [Abstract][Full Text] [Related]
4. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation.
Soiffer RJ; Murray C; Gonin R; Ritz J
Blood; 1994 Aug; 84(3):964-71. PubMed ID: 8043878
[TBL] [Abstract][Full Text] [Related]
5. High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study.
Pardo N; Martí F; Fraga G; Illa J; Badell I; Peiró M; Bertran E; García J; Rueda F; Cubells J
Med Pediatr Oncol; 1996 Dec; 27(6):534-9. PubMed ID: 8888813
[TBL] [Abstract][Full Text] [Related]
6. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
[TBL] [Abstract][Full Text] [Related]
7. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.
Thompson JA; Lee DJ; Lindgren CG; Benz LA; Collins C; Shuman WP; Levitt D; Fefer A
Cancer Res; 1989 Jan; 49(1):235-40. PubMed ID: 2783243
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of natural killer and lymphokine-activated killer (LAK) cell activity in vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells.
Walewski J; Paietta E; Dutcher J; Wiernik PH
J Cancer Res Clin Oncol; 1989; 115(2):170-4. PubMed ID: 2654134
[TBL] [Abstract][Full Text] [Related]
9. Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma.
Vaglini M; Belli F; Santinami M; Arienti F; Parmiani G; Persiani L; Santoro N; Grazia Inglese M; D'Elia F; Cascinelli N
Ann Surg Oncol; 1995 Jan; 2(1):61-70. PubMed ID: 7834457
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia--a phase I study.
Weisdorf DJ; Anderson PM; Blazar BR; Uckun FM; Kersey JH; Ramsay NK
Transplantation; 1993 Jan; 55(1):61-6. PubMed ID: 8420066
[TBL] [Abstract][Full Text] [Related]
11. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.
Bar MH; Sznol M; Atkins MB; Ciobanu N; Micetich KC; Boldt DH; Margolin KA; Aronson FR; Rayner AA; Hawkins MJ
J Clin Oncol; 1990 Jul; 8(7):1138-47. PubMed ID: 2358835
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastoma.
Negrier S; Michon J; Floret D; Bouffet E; Gentet JC; Philip I; Cochat P; Stamm D; Costil J; Gaspard M
J Clin Oncol; 1991 Aug; 9(8):1363-70. PubMed ID: 1830096
[TBL] [Abstract][Full Text] [Related]
13. Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients.
Blaise D; Viens P; Olive D; Stoppa AM; Gabert J; Pourreau CN; Attal M; Gaspard MH; Mannoni P; Jasmin C
Eur Cytokine Netw; 1991; 2(2):121-9. PubMed ID: 1813015
[TBL] [Abstract][Full Text] [Related]
14. Effective treatment of high-grade lymphoproliferative disorder after renal transplantation using autologous lymphocyte activated killer cell therapy.
Li PK; Tsang K; Szeto CC; Wong TY; To KF; Leung CB; Lui SF; Yu S; Lai FM
Am J Kidney Dis; 1998 Nov; 32(5):813-9. PubMed ID: 9820452
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 2 immunotherapy in children with neuroblastoma after high-dose chemotherapy and autologous bone marrow transplantation.
Favrot MC; Michon J; Floret D; Cochat C; Negrier S; Mathiot C; Coze C; Zucker JM; Franks CR; Bouffet E
Pediatr Hematol Oncol; 1990; 7(3):275-84. PubMed ID: 2206868
[TBL] [Abstract][Full Text] [Related]
16. A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma.
Kamani N; August CS; Bunin N; Leahey A; Bayever E; Goldwein J; Zusman J; Evans AE; Angio GD
Bone Marrow Transplant; 1996 Jun; 17(6):911-6. PubMed ID: 8807093
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group.
Matthay KK; Seeger RC; Reynolds CP; Stram DO; O'Leary MC; Harris RE; Selch M; Atkinson JB; Haase GM; Ramsay NK
J Clin Oncol; 1994 Nov; 12(11):2382-9. PubMed ID: 7964954
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies.
Fefer A; Robinson N; Benyunes MC; Bensinger WI; Press O; Thompson JA; Lindgren C
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S48-53. PubMed ID: 9457394
[TBL] [Abstract][Full Text] [Related]
19. [Adoptive immunotherapy with interleukin 2 in oncology].
Favrot M; Bouffet E; Négrier S; Combaret V; Philip I; Philip T
Bull Cancer; 1990; 77(9):925-31. PubMed ID: 2224165
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2 in neuroblastoma: clinical perspectives based on biological studies.
Rueda F; Martí F; Pardo N; Badell I; Peiró M; Bertran E; Villén E; García J; Cubells J
Cancer Biother Radiopharm; 1996 Oct; 11(5):303-8. PubMed ID: 10851509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
